Starling Oncology, Inc.
The Oncology Institute (TOI) provides outpatient cancer care and related services to adult and senior patients, including Medicare, Medicaid, and commercially insured populations. It operates through physician-owned affiliated practices and a network of independent clinics and providers across five states. Its services include medical oncology, hematology, infusion and radiation therapy, oral and specialty pharmacy, clinical trials, and palliative care. TOI serves patients through fee-for-service care and value-based contracts with payors and other risk-bearing entities. Fee-for-service services are billed for care provided, while value-based arrangements typically pay a fixed per-member amount for managing oncology care; some contracts share gains or losses against cost and quality measures. Under full-delegation contracts, TOI also manages services such as network administration, utilization management, and claims adjudication. Its corporate office is in Cerritos, California.
No SEC Form 4 filings for $DFPH in the last 30 days.
See all $DFPH insider activity →Starling Oncology (STLN) reported Q3 2026 revenue of $169.8M, up 24% YoY, and adjusted EBITDA of $3.4M. The company expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M, targeting 100% capitated revenue growth in 2027, according to management.
Oncology Institute (STLN) reported Q3 gross profit of $30.7M, up from $18.9M, with gross margin increasing to 18.1%. Capitated revenue rose 39.5% to $28.7M, while fee-for-service revenue fell 21% to $31.3M. The company expects 100% capitated revenue growth in 2027 and updated its 2026 outlook, including revenue of $650M-$660M and gross profit of $107M-$110M. STLN ended Q3 with $36.9M in cash.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning DFPH (Starling Oncology, Inc.). Coverage has been balanced: 2 bullish, 1 neutral, and 2 bearish.
Recent DFPH coverage spans earnings, corporate actions and insider activity.
Starling Oncology (STLN) reported Q3 2026 revenue of $169.8M, up 24% YoY, and adjusted EBITDA of $3.4M. The company expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M, targeting 100% capitated revenue growth in 2027, according to management.
Oncology Institute (STLN) reported Q3 gross profit of $30.7M, up from $18.9M, with gross margin increasing to 18.1%. Capitated revenue rose 39.5% to $28.7M, while fee-for-service revenue fell 21% to $31.3M. The company expects 100% capitated revenue growth in 2027 and updated its 2026 outlook, including revenue of $650M-$660M and gross profit of $107M-$110M. STLN ended Q3 with $36.9M in cash.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o
Starling Oncology (STLN) will release Q3 2026 financial results on Nov. 5, followed by a conference call at 5 p.m. ET. The call can be accessed live or via replay, and a webcast is available on the company's website. STLN is a community oncology care provider with over 100 clinics across five states.
Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
AlphAI scores every news story that mentions DFPH with an AI model for sentiment and relevance, and aggregates insider trades from Starling Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Starling Oncology (STLN) reported Q3 2026 revenue of $169.8M, up 24% YoY, and adjusted EBITDA of $3.4M. The company expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M, targeting 100% capitated revenue growth in 2027, according to management.
Oncology Institute (STLN) reported Q3 gross profit of $30.7M, up from $18.9M, with gross margin increasing to 18.1%. Capitated revenue rose 39.5% to $28.7M, while fee-for-service revenue fell 21% to $31.3M. The company expects 100% capitated revenue growth in 2027 and updated its 2026 outlook, including revenue of $650M-$660M and gross profit of $107M-$110M. STLN ended Q3 with $36.9M in cash.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o
Starling Oncology (STLN) will release Q3 2026 financial results on Nov. 5, followed by a conference call at 5 p.m. ET. The call can be accessed live or via replay, and a webcast is available on the company's website. STLN is a community oncology care provider with over 100 clinics across five states.
Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-elect
Hively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. (“SOM, LLC”), entered into a Credit Agreement (the “Revolving Loan Agreement”) among SOM, LLC, su
Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.
